About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Pittsburgh | 217 Studies

Clinical Trials Ovarian CancerPittsburgh

Ovarian Cancer Clinical Trials in Pittsburgh

Find 217 clinical trials for ovarian cancer near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 1-20 of 217 trials

WithdrawnIntensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC VaccinesThis study will evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv)…NCT02432378·Pittsburgh, Pennsylvania and 1 other RecruitingStudy of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) MutationThis is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients…NCT04890613·Santa Monica, California and 7 others CompletedStudy of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced CancersPhase 1a/1b does-escalation study of cabiralizumab alone and with nivolumab in advanced solid tumors.NCT02526017·Scottsdale, Arizona and 38 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

WithdrawnZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsThis Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent…NCT06161493·Pittsburgh, Pennsylvania

CompletedCOM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in…NCT04570839·Chicago, Illinois and 8 others

Active not recruitingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerThis phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or…NCT04092270·Aurora, Colorado and 10 others

CompletedStudy of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid TumorsThis is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-lymphocyte activation gene-3 (LAG-3) antibody TSR-033 alone, in combination with the anti-PD-1…NCT03250832·Los Angeles, California and 11 others

RecruitingEfficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab…NCT05281471·Mobile, Alabama and 32 others

UnknownTissue Bank of Biological Specimens From Patients With Gynecologic DiseaseThe purpose of this study is to create a tissue bank of gynecologic cancers and normal tissue for the study of cancer in order to better understand the changes occurring on a…NCT00299481·Washington D.C., District of Columbia and 6 others

TerminatedA Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR GenesA Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination…NCT04171700·Los Angeles, California and 18 others

UnknownPaclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal TumorsThis randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating…NCT01042522·Anchorage, Alaska and 218 others

CompletedStudy of Motexafin Gadolinium and Docetaxel for Advanced CancerThe primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced…NCT00120939·Pittsburgh, Pennsylvania

UnknownSymptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerThis randomized clinical trial is studying two different symptom management programs to see how well they work compared with usual care in patients with recurrent or persistent…NCT00958698·Phoenix, Arizona and 143 others

Active not recruitingTesting the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialThis phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal)…NCT05554328·Birmingham, Alabama and 294 others

Active not recruitingTesting the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerThis phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a…NCT02345265·Phoenix, Arizona and 19 others

CompletedVTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal CancerThe purpose of this study is to compare the overall survival of patients treated with VTX-2337 + pegylated liposomal doxorubicin (PLD) versus those treated with PLD alone in women…NCT01666444·Phoenix, Arizona and 135 others

TerminatedA Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid TumorsThe primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.NCT05256381·Whittier, California and 53 others

Active not recruitingBevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerThis phase II trial studies the side effects of bevacizumab and anetumab ravtansine or paclitaxel in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…NCT03587311·Orange, California and 22 others

CompletedhTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseThis is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 or INO-1401 alone or in combination with INO-9012, delivered by…NCT02960594·Detroit, Michigan and 5 others

CompletedStudy to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersThe purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers.NCT02178722·La Jolla, California and 23 others

Page 1 of 11Next

Other Conditions in Pittsburgh

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia